Related Experiment Video
Updated: May 17, 2026
A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells
Published on: March 28, 2021
GS-1101: a delta-specific PI3K inhibitor in chronic lymphocytic leukemia
Ines M Macias-Perez1, Ian W Flinn
1Hematologic Malignancies Research, Sarah Cannon Research Institute, 3322 West End Avenue, Suite 900, Nashville, TN 37203, USA. imaciasperez@gmail.com
Abstract:
Chronic lymphocytic leukemia (CLL) remains an incurable B-cell malignancy with many unanswered questions. While the cell of origin and etiology are still unknown, significant scientific progress has revealed numerous molecular targets for novel therapeutic interventions. Phosphatidylinositol 3-kinases (PI3K) regulate key cellular functions, including growth, survival and migration, by integrating and transmitting signals from diverse surface molecules including the B-cell receptor (BCR). In lymphocytes, the PI3Kδ isoform plays a critical role in B-cell homeostasis and function. In CLL, the PI3K pathway is constitutively active and dependent on PI3Kδ. GS-1101 is a highly selective PI3Kδ inhibitor that in CLL patients causes a rapid and sustained reduction in lymphadenopathy, accompanied by transient lymphocytosis. This article will review new insights into the pathophysiology of CLL, the preclinical rationale of a PI3Kδ inhibitor in CLL, and the clinical evidence supporting this first-in-class therapeutic target for CLL patients.
Insights
A novel drug targeting PI3Kδ, a key pathway in chronic lymphocytic leukemia (CLL), shows promise. This selective inhibitor effectively reduces lymphadenopathy in CLL patients, offering a new therapeutic avenue.
Area of Science:
- Oncology
- Immunology
- Molecular Biology
Background:
- Chronic lymphocytic leukemia (CLL) is an incurable B-cell malignancy with unknown origins.
- The phosphatidylinositol 3-kinase (PI3K) pathway is crucial for B-cell function and is constitutively active in CLL.
- The PI3Kδ isoform is critical for B-cell homeostasis and is a key dependency in CLL.
Purpose of the Study:
- To review insights into CLL pathophysiology.
- To discuss the preclinical rationale for PI3Kδ inhibitors in CLL.
- To present clinical evidence for GS-1101 as a first-in-class therapeutic target.
Main Methods:
- Review of existing literature on CLL pathophysiology.
- Analysis of preclinical data for PI3Kδ inhibitors.
- Examination of clinical trial results for GS-1101 in CLL patients.
Main Results:
- GS-1101, a selective PI3Kδ inhibitor, demonstrates efficacy in CLL.
- Treatment with GS-1101 leads to rapid and sustained reduction in lymphadenopathy.
- A transient lymphocytosis was observed in CLL patients treated with GS-1101.
Conclusions:
- The PI3K pathway, specifically PI3Kδ, is a validated therapeutic target in CLL.
- GS-1101 represents a promising first-in-class treatment for CLL.
- Further clinical investigation of PI3Kδ inhibitors is warranted for CLL management.
